title: Variability in the response to antiplatelet treatment in diabetes mellitus.
abstract: Atherothrombosis is a leading cause of death in patients with diabetes mellitus. Among factors contributing to the diabetic prothrombotic state, platelet activation plays a pivotal role. Numerous studies have investigated the benefits of antiplatelet therapy for primary and secondary cardiovascular prevention in diabetic patients. However, there are limited evidences that low-dose aspirin may be effective in this clinical setting. Several disease-specific factors have been identified as potential determinants of aspirin treatment failure. In this review, the main determinants of interindividual variability in response to antiplatelet agents are discussed, with particular emphasis on the pharmacokinetic and pharmacodynamic mechanisms of clinical efficacy and safety of antiplatelet drugs in patients with diabetes mellitus.
authors.affiliation: Internal Medicine and Center of Excellence on Aging, "G. D'Annunzio" University of Chieti, Italy. gdavi@unich.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Davì
authors.forename: Natale
authors.initials: N
authors.lastname: Vazzana
authors.forename: Simona
authors.initials: S
authors.lastname: Sestili
mesh_terms: D048909:Diabetes Complications / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy; D013931:Thromboxanes / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013931:Thromboxanes